3.3 Blood Component Quality Control
Key Takeaways
- Component QC uses statistical sampling of production lots against defined acceptance criteria — not every unit is tested, but each product type must meet its specification on a defined percentage of sampled units
- Key RBC QC parameters include hematocrit, hemoglobin content, and (for leukocyte-reduced units) residual white blood cell count ≤5 × 10^6 per unit with ≥85% original red cell recovery
- Key platelet QC parameters include platelet count/yield per unit, pH ≥6.2 at outdate, and swirling (a visual indicator of platelet discoid shape/viability)
- Plasma and cryoprecipitate QC centers on residual Factor VIII activity/content, since factor degradation over time and temperature excursions is the primary quality risk for these components
- QC failures require investigation, may trigger process review, and out-of-specification units must be removed from inventory rather than released on an exception basis
Blood Component Quality Control
Quick Answer: Blood component QC verifies, through statistical sampling of production, that processed components consistently meet defined specifications — leukocyte-reduced units must show residual WBC counts below a defined threshold with adequate red cell recovery, platelet units must meet count, pH, and swirling criteria, and plasma/cryoprecipitate must retain adequate Factor VIII activity. QC is a sampling program, not 100% unit-by-unit testing, and out-of-specification results require investigation and removal of affected product. This section covers the sampling logic and the specific acceptance criteria for major component types.
I.E — The Statistical Sampling Model
Unlike infectious disease testing (performed on every donation), most component QC parameters are verified through periodic statistical sampling of a facility's production — testing a defined number of units per month or per production lot against a specification, with a defined percentage of sampled units required to pass. This model exists because many QC tests (e.g., residual leukocyte counting, platelet pH) are destructive or resource-intensive, and the goal is to demonstrate that the process reliably produces conforming product, not to certify every individual unit. AABB Standards and FDA guidance specify minimum sampling frequencies and pass rates (e.g., "at least X units per month, with at least Y% meeting specification") for each component type and modification a facility produces.
When a sampled unit fails to meet specification, the facility must:
- Investigate the failure (equipment malfunction, process deviation, donor-specific factor)
- Determine scope — whether the failure implicates only that unit or a broader production lot/time period
- Take corrective action — process adjustment, equipment recalibration, retraining
- Document per the quality system, since QC records are inspected by AABB/FDA/CAP surveyors
A QC failure does not automatically mean every unit from that period must be recalled, but it does trigger a documented investigation and often increased sampling until the process is shown to be back in control.
Red Blood Cell QC
| Parameter | Typical Acceptance Criterion | Rationale |
|---|---|---|
| Hematocrit | Generally 65–80% (depends on additive solution use) | Ensures adequate red cell mass per unit without excessive viscosity |
| Hemoglobin content | Facility-defined minimum per unit | Ensures clinically meaningful red cell mass delivered |
| Residual leukocytes (leukocyte-reduced units) | ≤5 × 10^6 white blood cells per unit | Reduces febrile nonhemolytic reactions, HLA alloimmunization, and CMV transmission risk |
| Red cell recovery (leukocyte-reduced units) | ≥85% of original red cell content retained | Confirms filtration/processing did not excessively strip red cell mass |
| Sterility | No growth on periodic culture sampling | Confirms aseptic processing |
| Hemolysis (at outdate) | Generally <0.8% hemolysis by outdate | Excessive hemolysis indicates storage lesion beyond acceptable limits |
Leukocyte reduction QC is one of the most heavily tested concepts: the ≤5 × 10^6 residual WBC threshold (per unit, for units labeled "leukocyte-reduced") is what prevents most febrile nonhemolytic transfusion reactions and reduces CMV transmission and HLA alloimmunization risk, and is verified either by pre-storage or post-storage flow cytometric/microscopic leukocyte counting on a statistically sampled subset of production.
Platelet QC
| Parameter | Typical Acceptance Criterion | Rationale |
|---|---|---|
| Platelet count/yield | Whole-blood-derived: generally ≥5.5 × 10^10 per unit; apheresis: generally ≥3.0 × 10^11 per unit | Ensures adequate dose for hemostatic effect |
| pH at outdate | ≥6.2 (measured at 22°C at end of storage period) | Declining pH reflects lactic acid accumulation from platelet metabolism; low pH correlates with loss of platelet viability and discoid shape |
| Swirling | Visible swirling (light-scattering pattern from discoid platelets) present | A simple visual QC and release check — loss of swirl suggests platelet shape change/activation and possible bacterial contamination, and should prompt further evaluation before issue |
| Volume | Facility-defined range per product type | Ensures adequate plasma/additive carrier volume for storage chemistry |
| Residual leukocytes (leukoreduced platelets) | ≤5 × 10^6 per unit | Same rationale as leukoreduced RBCs |
| Bacterial contamination screening | Negative culture/rapid test result | Platelets' room-temperature storage makes bacterial growth the highest-severity infectious risk among routine components |
Swirling deserves special attention: it is a rapid, non-destructive, at-the-bedside-capable visual check performed by holding the bag against light and looking for a shimmering/turbulent light-scattering pattern created by normal discoid (disc-shaped) platelets. Loss of swirl is a red flag — it can indicate platelet activation/shape change from storage lesion, temperature excursion, or (concerning) bacterial contamination, and a platelet unit without visible swirl should not be issued for transfusion without further evaluation.
Plasma and Cryoprecipitate QC
| Parameter | Typical Acceptance Criterion | Rationale |
|---|---|---|
| Factor VIII activity/content (FFP) | Generally ≥70 IU per 100 mL, or facility-defined minimum international units per unit | FFP's principal clinical value depends on retained coagulation factor activity, and Factor VIII is the most labile factor, making it the sentinel marker for adequate freezing/processing speed |
| Factor VIII content (Cryoprecipitated AHF) | Generally ≥80 IU per unit (varies by regulatory standard/region) | Cryoprecipitate is specifically manufactured to concentrate Factor VIII, fibrinogen, von Willebrand factor, and Factor XIII from thawed FFP |
| Fibrinogen content (Cryoprecipitated AHF) | Generally ≥150 mg per unit | Fibrinogen is a key clinical indication for cryoprecipitate use |
| Residual leukocytes | Not typically a plasma QC parameter (acellular product) | Plasma processing removes cellular content by centrifugation |
Factor VIII is used as the QC sentinel for plasma products because it is the most time- and temperature-sensitive coagulation factor — if processing is too slow or storage temperature drifts, Factor VIII activity drops measurably before other factors are significantly affected, making it a sensitive early-warning marker for process problems.
Why QC Parameters Matter Beyond Memorization
SBB exam items on component QC tend to test the relationship between a parameter and what it protects against — for example, connecting residual WBC limits to febrile reactions and CMV risk, connecting platelet pH/swirl to viability and bacterial risk, and connecting Factor VIII content to processing speed. Understanding why each threshold exists supports reasoning through unfamiliar specific numeric values that may appear on an exam item, since acceptance criteria can be phrased differently across AABB Standards editions, FDA guidance, and international standards (e.g., Council of Europe) without changing the underlying clinical rationale.
Documentation and Corrective Action
QC data must be trended over time, not just evaluated pass/fail per unit, because a gradual drift toward the specification limit (even without a single outright failure) can signal an emerging process problem — for example, residual WBC counts creeping upward across several months of sampling might indicate filter lot variation or a processing timing issue worth investigating before an actual failure occurs. This proactive trending is a hallmark of a mature quality system and is frequently emphasized in SBB-level (versus generalist) quality assurance content, since laboratory administration and quality oversight are core SBB-specific competencies.
What is the primary clinical rationale for the ≤5 × 10^6 residual white blood cell limit on leukocyte-reduced blood components?
A platelet unit is checked prior to issue and shows no visible swirling pattern when held to light. What should this prompt?
Why is Factor VIII activity used as the sentinel QC parameter for fresh frozen plasma rather than another coagulation factor?